Management of thalassemia: Difference between revisions
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
==== Deferiprone ==== | ==== Deferiprone ==== | ||
[[Deferiprone]] is an oral iron chelator that offers a more convenient alternative to deferoxamine. It is particularly effective in removing iron from the heart, reducing the risk of cardiac complications. Deferiprone is often used in combination with other chelators to enhance efficacy. | [[Deferiprone]] is an oral iron chelator that offers a more convenient alternative to deferoxamine. It is particularly effective in removing iron from the heart, reducing the risk of cardiac complications. Deferiprone is often used in combination with other chelators to enhance efficacy. | ||
Latest revision as of 15:06, 22 February 2025
Management of Thalassemia[edit]
The management of thalassemia involves a combination of regular blood transfusions, iron chelation therapy, and supportive treatments to manage complications. Thalassemia is a genetic blood disorder characterized by the body’s inability to produce adequate amounts of hemoglobin, leading to anemia and other health issues.
Blood Transfusions[edit]
Regular blood transfusions are a cornerstone in the management of thalassemia, particularly for patients with thalassemia major. These transfusions help maintain hemoglobin levels, reduce symptoms of anemia, and improve quality of life. However, repeated transfusions can lead to iron overload, necessitating the use of iron chelation therapy.
Iron Chelation Therapy[edit]
Iron chelation therapy is essential for patients receiving regular blood transfusions to prevent iron overload, which can damage vital organs such as the heart, liver, and endocrine system. Several iron chelators are used in the management of thalassemia:
Deferoxamine[edit]

Deferoxamine is an iron chelator administered via subcutaneous or intravenous infusion. It binds to excess iron, forming a complex that is excreted from the body. Deferoxamine is effective but requires prolonged infusion times, which can be inconvenient for patients.
Deferiprone[edit]
Deferiprone is an oral iron chelator that offers a more convenient alternative to deferoxamine. It is particularly effective in removing iron from the heart, reducing the risk of cardiac complications. Deferiprone is often used in combination with other chelators to enhance efficacy.
Deferasirox[edit]

Deferasirox is another oral iron chelator that is widely used due to its once-daily dosing regimen. It binds to iron and facilitates its excretion through the feces. Deferasirox is effective in reducing liver iron concentration and is well-tolerated by most patients.
Supportive Treatments[edit]
In addition to blood transfusions and iron chelation, patients with thalassemia may require other supportive treatments. These can include:
- Folic acid supplementation to support red blood cell production.
- Splenectomy in cases of splenomegaly or hypersplenism.
- Bone marrow transplantation or stem cell transplantation as potential curative options for some patients.
Monitoring and Follow-up[edit]
Regular monitoring of iron levels, organ function, and overall health is crucial in the management of thalassemia. This includes:
- Routine blood tests to monitor hemoglobin levels and iron status.
- Imaging studies such as MRI to assess iron deposition in organs.
- Regular cardiac and liver function tests.